Indication
Essential
7 clinical trials
13 products
Clinical trial
A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients With Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical StudyStatus: Active (not recruiting), Estimated PCD: 2024-08-22
Product
BomedemstatProduct
AD-209Product
AD-209-1AProduct
AD-209-1BProduct
AD-209-1CClinical trial
A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential HypertensionStatus: Completed, Estimated PCD: 2023-11-27
Product
AD-209-1Product
ES-481Clinical trial
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients With Essential TremorsStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Cardiovascular Effects of Angiotensin (1-7) in Essential HypertensionStatus: Terminated, Estimated PCD: 2023-12-01
Product
Angiotensin (1-7)Product
TrimethaphanProduct
PhenylephrineClinical trial
A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical StudyStatus: Recruiting, Estimated PCD: 2034-12-04
Clinical trial
A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022 in Patients With Primary Hypercholesterolemia and Essential HypertensionStatus: Completed, Estimated PCD: 2021-11-22
Product
AD-2021Product
AD-2022Clinical trial
An Investigator Initiated Phase 2 Trial of the LSD1 Inhibitor IMG-7289 in Essential Thrombocythemia (CTMS# 19-0078)Status: Recruiting, Estimated PCD: 2024-01-01
Product
IMG-7289